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Computed
Tomography Angiography
MSCT to Diagnose In-Stent Restenosis
As the spatial and temporal resolutions of multislice computed tomography(MSCT) improve, it may be feasible to diagnose in-stent restenosis (ISR). Ehara
and colleagues performed MSCT on 81 patients with previous stenting followed
within 5 days by conventional coronary angiography. The sensitivity for detecting
binary restenosis was 92%, although the positive predictive value was only 54% as
the severity of 6 lesionswas overestimatedbyMSCT.Thehigh sensitivity ofMSCTfor
detecting ISR suggests that it may be a useful screening test. See page 951.
See figure.
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Heart Failure
Carvedilol Reduces Stroke and MIs Compared to Metoprolol
The COMET study randomized over 3,000 subjects with an ejection fraction35%to either carvedilol ormetoprolol tartate; carvedilol reduced the likelihood
of death by 20%. In this study, Remme and colleagues further analyzed the data to
determine if there were differences in the rates of stroke and myocardial infarction
(MI). Carvedilol resulted in improved hazard ratios for MI (0.71), stroke (0.79), and
fatal stroke or fatal MI (0.46). This study suggests that the full adrenergic blockade of
carvedilol and its antioxidative effectsmay lead to improved vascular protection relative
to beta-1 blockade alone. See page 963. See figure.
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Heart Failure
Larger Hearts, Higher Stroke Volumes for Those With HFPEF
The Cardiovascular Health Study has acquired echocardiograms and clinical andepidemiologic data on almost 6,000 elderly subjects. Subjects with a history of
heart failure and preserved ejection fraction (HFPEF) were older, more obese, and
more often African American than other subjects. The left ventricular diastolic dimen-
sion was significantly increased in HFPEF subjects (5.2 cm) compared to both those
with hypertension but no heart failure (4.9) and non-hypertensive subjects (4.8).
Stroke volume and cardiac output were also increased. Subjects with HFPEF had an
increasedprevalence of several comorbidities, including anemia, renal dysfunction, and
obesity, that can cause volume overload. This study suggests that extra-cardiac factors,
via volume overload, may contribute to the pathophysiology of HFPEF, rather than
intrinsic properties of the ventricle such as stiffness. See page 972. See figure.
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Heart Rhythm Disorders
No Improvement in AF Mortality Over the Last 20 Years
Although treatment strategies for atrial fibrillation (AF) have changed over the last20years, there is limiteddata on the effect of these changes onmortality.Miyasaka
and colleagues used a community-based cohort of patients with a new diagnosis of AF
from1980 to 2000. There were 2 interesting findings. Themortality fromAF remains
high; overall, patients with newly diagnosed AF are twice as likely to die as an age- and
gender-adjusted cohort. This excess mortality is especially high in the first 4 months.
The second interestingfinding is that overall there has beenno substantial change in life
expectancy for AF over the last 20 years. This study suggests there is a need for
improvement in the treatment of AF. See page 986. See figure.
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Congenital Heart Disease
Endovascular Therapy for SVC Occlusion
Tzifa and colleagues report on their experience treating 63 patients with obstruc-tion of the superior vena cava (SVC). Causative factors were previous congenital
cardiac surgery, extracorporeal membrane oxygenation, chronic central venous cathe-
ter, and external compression from a tumor. Adequate relief was achieved in all
patients after stent implantation and in 78% with balloon dilation alone. There were
no deaths associated with the procedure. Twenty percent of patients suffered a com-
plication, but only 2 patients required emergency surgery. Patients who have under-
gone previous cardiac surgery are at higher risk for complications, especially tears at the
SVC–right atrial junction. This report demonstrates that percutaneous treatment of
SVCocclusion is possible and can substantially improve symptoms fromSVCobstruc-
tion. See page 1003. See figure.
